Shares of Eli Lilly surged over 10% on Wednesday, adding nearly $100 billion in market value after the pharmaceutical giant reported substantial earnings results. The company’s fourth-quarter revenue soared 43% year-over-year, reaching $19.3 billion, primarily driven by the remarkable performance of its diabetes and obesity treatments, Mounjaro and Zepbound. Sales for Mounjaro skyrocketed by 110% to $7.4 billion, while Zepbound saw a staggering 123% increase, bringing in $4.3 billion.
In response to the escalating demand for its highly sought-after GLP-1 medications, Eli Lilly has been rapidly expanding its manufacturing capabilities. This effort has gained urgency following a recent agreement with the U.S. government, which is expected to enhance access to Mounjaro and Zepbound for Medicare beneficiaries at reduced prices. Notably, Eli Lilly’s competitive edge in the obesity drug sector has been reinforced by positive clinical trial results, which demonstrated that Zepbound produced greater weight loss compared to Novo Nordisk’s Wegovy. According to Chief Financial Officer Lucas Montarce, Zepbound now commands nearly 70% of the market for new prescriptions in the branded obesity drug category.
In terms of financial performance, Eli Lilly’s adjusted net income surged by 41% to $6.8 billion, translating to earnings of $7.54 per share. This figure substantially exceeded analysts’ expectations, with forecasts predicting a profit of $6.91 per share.
Looking ahead, Eli Lilly provided an optimistic growth outlook, projecting a revenue increase of approximately 25% by 2026, aiming for total revenues between $80 billion and $83 billion. Adjusted earnings per share are expected to rise by around 40%, targeting a range of $33.50 to $35.00. Chief Scientific Officer Daniel Skovronsky noted the company’s commitment to innovation and development, asserting, “This past year was busy and productive, and we expect more of the same in 2026 as we continue to create meaningful medicines on behalf of the patients that need us.”
With strong financial results and a promising growth trajectory, Eli Lilly’s market optimism reflects its significant position in the evolving healthcare landscape, particularly in the diabetes and obesity treatment sectors.
